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Abstract
We present a model analysis of the tumor and normal cell growth under the influence of
a carcinogenic agent, an immunomdulator (IM) and variable influx of immune cells including
relevant interactions. The tumor growth is facilitated by carcinogens such as inorganic arsenic
while the IM considered here is black tea (Camellia sinesnsis). The model with variable influx
of immune cells is observed to have considerable advantage over the constant influx model,
and while the tumor cell population is greatly mitigated, normal cell population remains
above healthy levels. The evolutions of normal and tumor cells are computed from the
proposed model and their local stabilities are investigated analytically. Numerical simulations
are performed to study the long term dynamics and an estimation of the effects of various
factors is made. This helps in developing a balanced strategy for tumor mitigation without
the use of chemotherapeutic drugs that usually have strong side-effects.
Keywords: Tumor growth dynamics; Immune response; Mathematical model; Next gener-
ation matrix; Basic reproduction number; Stability.
AMS subject classification: 93A30; 93D20; 37B25; 37N25.
1 Introduction
The scourge of cancer is on the rise all around the globe. There have been a number of factors
responsible for this increasing trend. Cancer is one of the leading causes of death and according
to 2018 GLOBOCAN data, death due to cancer stands at 9.6 million in 2018 [1]. Cancer
is an uncontrolled and abnormal proliferation of cells, leading to formation of tumour which
can infiltrate and destroy normal tissues. There have a number of etiologic factors responsible
for this disease, including environmental exposures, lifestyle and others. Often there is some
occupational exposure to certain carcinogenic risk-factors like chemicals, radioactive materials
etc.
∗ravieroy123@gmail.com, ravieroy123@iitkgp.ac.in
†abbas@iitmandi.ac.in
1
Arsenic, a metalloid, is found in abundance in ground water in many parts of the world.
Exposure to arsenic leads to a plethora of health hazards [2]. The United States’ Environ-
mental Protection Agency declared that all arsenic is a potential risk to human health [3]. In
the list of hazardous substances, the United States’ Agency for Toxic Substances and Disease
Registry ranked arsenic as number 1 [4]. Ingestion of arsenic through drinking water is a global
catastrophe and millions of people are affected, particularly in the under-developed world.
Of the two forms of arsenic, namely organic and inorganic, inorganic Arsenic (iAs) is a
potential cause of cancer. There are two inorganic forms of iAs and they are more toxic than
the organic forms. These inorganic forms are capable of generation of reactive oxygen species
(ROS), leading to DNA, protein and lipid damage. The major cause of arsenic toxicity in
humans is through consumption of iAs-contaminated water [5]. Contamination of ground water
with this silent poison is a global problem.
Administration of cytotoxic drugs, as in chemotherapy, destroys the cancer cells, or slows
down their rapid division. Besides killing the cancer cells, these cytotoxic drugs also damage
normal cells. Chemotherapeutic agents often lower the immune response, therefore, a combina-
tion of chemotherapy with an immune stimulatory agent might be a promising regimen to treat
cancer. An immunomodulator may pave the way to a successful treatment strategy. Any agent
which boosts immunity with minimal side effects is highly desirable. Natural plant biomolecules
are endowed with a number of health-beneficial properties. Many of the natural plant products
have enormous anticancer potential. Chemoprevention is therefore a promising strategy that can
retard, revert or prevent the progression of cancer and block the development at the initiation
stage by use of natural products.
iAs is a known inducer of ROS, which in turn triggers a number of events promoting car-
cinogenesis. Therefore, an antioxidant may aid in tackling it. Tea, the most popular beverage
around the globe is a good antioxidant. Therefore, studies were undertaken to mitigate car-
cinogenesis by employing black tea (BT). Among a number of cancers, exposure to iAs causes
skin carcinoma. The fact that BT quenches ROS in Swiss albino mice and inhibits iAs-induced
skin cancer is already known [2] from experiments carried out on Swiss albino male mice (Mus
Musculus) in the laboratory of one of us. A mathematical model was also developed [6] based
on the experimental data.
Besides its antioxidant potential, BT has several other attributes, one such is its immunomod-
ulatory role. Immunotherapy is yet another type of treatment given to patients, which aims to
reinforce patients’ own immune response against the growth of cancer cells. The IM regulates the
immune function of the normal physiological process and also tries to maintain a healthy immune
response in altered physiological conditions. Black tea has been recognized as an immunomod-
ulator in Ayurvedic medicine. The immunomodulatory effects of tea has also been observed
in mice [7, 8, 9]. In this paper, we build upon the previous experimental work and modelling
on the effects of BT on tumor growth[6]. A point of departure from earlier models [10, 11] is
the inclusion of variable influx of immune cells facilitated primarily by the immunomodulatory
effects of BT. Along with the variable influx, the positive interaction between tea and immune
cells is also included.
2 The Model
In this section we describe the model in detail. As discussed above, we do not use chemotherapy
to destroy the cancer cells and instead include the effects of BT in reducing tumor growth (albeit
through the reduction of ROS) and the modulation of immunity.
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2.1 The Model —Overview
The model presented has following components:
1. Arsenic as stimulator of tumor: iAs as an external source to stimulate the growth of
tumor. We emphasize that while we consider iAs as driving the tumor growth, based on
the experiments discussed above, it can, in general, be viewed as any carcinogen present
in the environment to which exposure is common.
2. Immune Response: The model includes immune cells whose growth may be stimulated by
the presence of tumor. These cells can inhibit the growth of tumor cells. Their effects are
taken in the model via the usual kinetic process. The important addition to usual models
is a variable influx, s(t) in the evolution of immune cells. This reflects the fact that the
immune response is ideally never constant and the body can produce variable amounts of
immune cells at different stages of response.
3. Competition Terms: Normal cells and tumor cells compete for available resources, while
immune cells and tumor cells compete in predator-prey fashion.
4. BT-Response: BT has mitigating effects on cancer growth (via ROS reduction) and there-
fore a term representing such effects is included [6]. The model also includes BT-tumor
interaction, as well as BT-immune cell interaction. The beneficial effect of BT is seen
through the suppression of tumor cells and strengthening of the immune cells, and it has
no known adverse effects on the normal cells unlike chemotherapy.
2.2 Constructing the Model
Both the normal and tumor cells independently increase according to the usual logistic growth
law. The interaction between normal and tumor cells is of predator-prey type, described by the
following system of equations, where normal cells are denoted 1 by N and the tumor cells are
denoted by T.
dN
dt
= r2N (1− b2N)− c1TN
dT
dt
= r1T (1− b1T )− c′1TN
The interaction terms c1 and c
′
1 are competition terms and are both assumed to be positive. A
negative competition term would imply that instead of the normal cells destructively competing
with the tumor cells for resources and space, the presence of the normal cells would in fact
stimulate further growth of the tumor cell population. While some authors argue that c′1 could
be negative [12, 13], we assume a destructive competition in this study.
The inclusion of arsenic in the system has deleterious effects on normal cells, and a certain
proportion of normal cells become tumorous. It is represented by the following terms
dN
dt
= −α′AN and dT
dt
= αAN
1We let N(t)(≡ N) denote the number of normal cells at time t, T (t)(≡ T ) denote the number of tumor cells
at time t, I(t)(≡ I) denote the number of immune cells at time t, and s(t)(≡ s) denote the variable influx of
immune cells. A(t)(≡ A) and D(t)(≡ D) are the Arsenic and BT respectively.
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It is possible that not all of the normal cells turn into tumorous, as iAS can also result in
the death of normal cells. In earlier studies, a constant influx rate has been assumed for the
immune cells. The assumption has been relaxed here to accommodate real immune responses,
which is variable, and along with a steady rate, production of immune cells at a rate of η is
allowed. This is represented by the term
η
b+ s
s
To avoid immune cell proliferation and immune-upon-immune crowding, a saturation value
is assumed. The presence of tumor cells stimulates the immune response, represented by the
positive nonlinear growth term for the immune cells:
ρIT
α1 + T
where ρ and α1 are positive constants. This type of response terms is of the same form as used
in the models of Kuznetsov et.al. [14]. Moreover, the reaction of immune cells and tumor cells
can result in either the death of tumor cells or the deactivation of the immune cells, represented
by two competition terms
dT
dt
= −βIT and dI
dt
= −β′IT
Arsenic and BT considered in the model have a simple form: there is a steady influx of
both and a decay with certain rates. The presence of BT is assumed to stimulate the immune
response and hence a term similar to Michaelis-Menten equation is assumed. BT also has an
adverse effect on the tumor, and both these effects are represented:
dT
dt
= −γDT and dI
dt
= δID
α2+D
2.3 The Model —Equations
Combining all these terms, we propose and analyze the model described by the following system
of equations:
dN
dt
= r2N (1− b2N)− c1TN − α′AN
dT
dt
= r1T (1− b1T )− c′1TN + αAN − βIT − γDT
dI
dt
= s(t) +
ρIT
α1 + T
− dII − β′IT + δID
α2 +D
(1)
dA
dt
= a0 − dAA
dD
dt
= b0 − dDD
ds
dt
= s0 +
η
b+ s
s− µ1s.
2.3.1 Description of Parameters:
In this section, we summarize the parameters of the mathematical model presented. This pa-
rameter set may vary depending on the case one is analysing. However, the analyses of the
model are quite general and hence they still apply. The idea is to keep the tumor population as
low as possible with normal cell count above a healthy threshold. We start with a small amount
of tumor cells and immune cells while initial values of arsenic and BT are zero.
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• Per unit growth rates: r1 and r2 are growth rates for tumor cells and normal cells respec-
tively. Here, we assume the tumor cell population grows more rapidly than the normal
cell population, and let r1 > r2.
• Carrying capacities: b−11 ≤ b−12 = 1.
• Competition terms: c1, c′1, α, α′, β β′ and γ are competition terms.
• Death rates: dI , dA and dD are per capita death rates of immune cells, arsenic, BT
respectively; µ1 is the death rate of the stimulated immune cells. a0 and b0 are constants,
assumed 0.4 here.
• Immune source rate: The immune source rate is considered to be variable here, denoted
by s(t). The influx of immune cells is to be stimulated from outside; s0 is the constant
influx; η is the production rate, b is the saturation term and µ1 is decay constant.
• Immune response rate: ρ, which is assumed to have a baseline value of 1. In the study
below, we set ρ = 0.01 to simulate a compromised immune system.
• Immune threshold rate: α1, is inversely related to the steepness of the immune response
curve.
• BT-Immune term: The BT-immune term is modelled similar to Michaelis-Menten term,
with α2 as threshold rate and δ as response rate.
We first analyse the equations analytically for positivity, boundedness, equilibrium points
and the stability of the solutions. We also look at possible instabilities. Thereafter, we work out
the dynamics and relevant phase diagram numerically.
3 Positivity and Boundedness of Solutions
The system (1) has initial conditions given by N(0) = N0 ≥ 0, T (0) = T0 ≥ 0, I(0) = I0 ≥ 0,
A(0) = A0 ≥ 0, D(0) = D0 ≥ 0, and s(0) = s0 ≥ 0.We consider all the variables and parameters
of the model to be non-negative, since the model investigates cellular populations. Based on the
biological findings, we analyze the system (1) in the region Ω =
{
(N,T, I,A,D, s) ∈ R6+
}
. We
first assure that the system (1) is well posed such that the solutions with non-negative initial
conditions remain non-negative for all 0 < t < ∞ and thus making the variables biologically
meaningful.
Theorem 3.1. The region Ω ⊂ R6+ given by Ω =
{
(N,T, I,A,D, s) ∈ R6+ : N ≤
1
b2
}
is posi-
tively invariant with respect to system of equations (1) and non-negative solutions exist for all
time 0 < t <∞.
Proof. Let Ω ⊂ R6+ given by Ω =
{
(N,T, I,A,D, s) ∈ R6+ : N ≤
1
b2
}
. Then the solutions
(N(t), T (t), I(t), A(t),D(t), s(t)) of (1) are positive for all t ≥ 0. It can be observed from the
first compartment that
dN
dt
= r2N − b2N2 − c1TN − α′AN ≤ r2N − b2N2.
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Using Bernoulli method and considering N(0) = N0, we obtain
N(t) ≤ 1
b2 + ke−r2t
, (2)
where k =
1−N0b2
N0
. Thus N0 =
1
b2 + k
. Substituting the value of k in (2), we obtain
N(t) ≤ 1
b2 +
1−N0b2
N0
e−r2t
≤ 1
b2
as t→∞.
Since b2 > 0, we have N(t) > 0 for all t > 0.
Similarly we can show that T (t) > 0, I(t) > 0, A(t) > 0, D(t) > 0 and s(t) > 0.
4 Equilibrium points
In this section, we discuss the existence of all possible equilibrium points of system (1). The
model system (1) admits four equilibrium points, one tumor-free equilibrium point, two dead
equilibrium points and one co-existing equilibrium point P∗ = (N
∗, T ∗, I∗, A∗,D∗, s∗) respec-
tively. We have N∗ > 0, T ∗ > 0, I∗ > 0, A∗ > 0,D∗ > 0, s∗ > 0 since cell populations are
non-negative and real. All parameters are also positive.
• Tumor-Free equilibrium point (TFE):
P0 = (
0.4α′ − dAr2
0.4α′b2
, 0,
s∗(dDα2 + 0.4)
d1(dDα2 + 0.4) − 0.4δ ,
0.4
dA
,
0.4
dD
, s∗), where s∗ is the real positive so-
lution of equation µ1s
2 + s(µ1b− η − s0)− bs0 = 0.
• Dead equilibrium point: An equilibrium point is said to be dead equilibrium, if the normal
cell population is zero. For d1α2 > (δ − d1)0.4
dD
, we have two dead equilibria in this case.
1. Type 1 Dead equilibrium point
Pd1 = (0, 0,
s∗(dDα2 + 0.4)
d1(dDα2 + 0.4) − 0.4δ ,
0.4
dA
,
0.4
dD
, s∗).
2. Type 2 Dead equilibrium point
Pd2 = (0,m
∗,
s∗(dDα2 + 0.4)
d1(dDα2 + 0.4) − 0.4δ ,
0.4
dA
,
0.4
dD
, s∗). Here m∗ is the real positive solu-
tion of equation T 3 +AT 2 +BT + C = 0, where
A =
1
β′r1b1
(
−r1b1ρ+ d1r1b1 + β′α1r1b1 − β′r1 − β′γD∗ + δD
∗r1b1
α2 +D∗
)
B =
1
β′r1b1
(s∗β + r1ρ+ ργD
∗ + d1α1r1b1 − d1r1 − d1γD∗ − β′α1r1 − β′α1γD∗
− δαD
∗r1b1
α2 +D∗
+
δD∗(r1 + γD
∗)
α2 +D∗
)
C =
1
β′r1b1
(
s∗βα1 − d1α1r1 − d1α1γD∗ + δD
∗α(r1 + γD
∗)
α2 +D∗
)
D∗ =
0.4
dD
.
• Co-existing equilibrium point P∗ = (N∗, T ∗, I∗, A∗,D∗, s∗)
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5 The Reproduction Number and Tumor-Free Equilibrium Point
In this section, we find the basic reproduction number by following the next generation matrix
methods as described in [15, 16]. At TFE, the matrices F and V are given as follows:
F =
(
r1 αN
∗
0 0
)
and V =
(
c′1N
∗ + βI∗ + γD∗ 0
0 dA
)
.
Then the basic reproduction number R0 is given by the largest eigenvalue of FV
−1. Thus,
we have
R0 =
r1r2b2dA [d1 (α2dD + 0.4) − 0.4δ]
(d1 (α2dD + 0.4) − 0.4δ) (r2dAc′1 − 0.4α′c′1 + 0.4γb2r2) + b2r2dAβs∗ (α2dD + 0.4)
(3)
The Basic reproduction number R0, which measures the rate of spread of tumor; R0 > 1, if each
cell produces on average more than one cell and thus the tumor grows over time. If R0 < 1, then
each cell produces on average less than one new cell and thus the therapy (drug administration)
can eradicate the tumor. At each time step, a tumor cell either produces an offspring or dies.
6 Stability Analysis
6.1 Local stability of Tumor-free equilibrium
Theorem 6.1. The Tumor-free equilibrium point P∗ = (N
∗, 0, I∗, A∗,D∗, s∗) is locally asymp-
totically stable, if the following Routh-Hurwitz criterion is satisfied,
B4 +B7 < 0 (4)
B4B7(B4 +B7) +B1B3B7 < 0.
along with
bη
(b+ s∗)2
< µ1, otherwise unstable, where B
′
is are as defined in (5).
Proof. Linearizing system (1) around TFE P0, we obtain the following Jacobian matrix J(P0)
J(P0) =


0 B1 0 B2 0 0
B3 B4 0 B5 0 0
0 B6 B7 0 B8 1
0 0 0 B9 0 0
0 0 0 0 B10 0
0 0 0 0 0 B11


where
B1 =
−c1(r2dA − 0.4α′)
b2r2dA
, B2 =
−α′(r2dA − 0.4α′)
b2r2dA
(5)
B3 =
0.4α
dA
, B4 = r1 − c′1N∗ − βI∗ − γD∗
B5 =
α(r2dA − 0.4α′)
b2r2dA
, B6 =
ρ
α1
− βI∗
B7 =
0.4δ
0.4 + α2dD
− d1, B8 = α2δI
∗
(α2 +D∗)2
B9 = −dA, B10 = −dD, B11 = bη
(b+ s∗)2
− µ1.
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Then the characteristic equation is given by∣∣∣∣∣∣∣∣∣∣∣∣
−λ B1 0 B2 0 0
B3 B4 − λ 0 B5 0 0
0 B6 B7 − λ 0 B8 1
0 0 0 B9 − λ 0 0
0 0 0 0 B10 − λ 0
0 0 0 0 0 B11 − λ
∣∣∣∣∣∣∣∣∣∣∣∣
= 0
Solving this determinant, we obtain the following equation:
(λ−B9)(λ−B10)(λ−B11)
(
λ3 +A1λ
2 +A2λ+A3
)
= 0. (6)
where A1 = −(B4 +B7), A2 = B4B7 and A3 = B1B3B7. Clearly the characteristic equation (6)
has three roots given by λ = B9 = −dA < 0, λ = B10 = −dD < 0, λ = B11 = bη
(b+ s∗)2
− µ1 < 0.
We are left with the cubic equation λ3 + A1λ
2 + A2λ + A3 = 0. Applying Routh-Hurwitz
criterion, the Tumor-free equilibrium is locally asymptotically stable, provided A1 > 0 and
A1A2 −A3 > 0.
6.2 Local stability of Dead equilibrium point
Theorem 6.2. The Type 1 Dead equilibrium point Pd1 = (0, 0, I
∗, A∗,D∗, s∗) is locally asymp-
totically stable provided the following hold;
r2 <
0.4α′
dA
, µ1 >
bη
(b+ s∗)2
, r1 < βI
∗ + γD∗, d1 >
0.4δ
0.4 + α2dD
. (7)
Proof. The characteristic equation corresponding to Pd1 is given by
(r2−α′A∗−λ)(r1−βI∗−γD∗−λ)(−d1+ δD
∗
α2 +D∗
−λ)(−dA−λ)(−dD−λ)( bη
(b+ s∗)2
−µ1−λ) = 0.
(8)
Clearly the roots of characteristic equation (8) are r2 − α′A∗ < 0, r1 − βI∗ − γD∗ < 0,−d1 + δD
∗
α2 +D∗
< 0,
−dA < 0, −dD < 0 and bη
(b+ s∗)2
− µ1 < 0. Thus the dead equilibrium Pd1 is locally asymptot-
ically stable.
6.3 Local stability of Endemic equilibrium point
Theorem 6.3. The co-existing equilibrium point P∗ = (N
∗, T ∗, I∗, A∗,D∗, s∗) is locally asymp-
totically stable, if the following Routh-Hurwitz criterion is satisfied,
A1 +A4 +A7 < 0 (9)
(A1 +A4)(A1A4 +A1A7 +A4A7 +A
2
7 −A2A3) +A5A6 < 0.
otherwise unstable, where A′is are as defined in (10)
Proof. The characteristic equation of system (1) corresponding to P∗ is given by∣∣∣∣∣∣∣∣∣∣∣∣
A1 − λ A3 0 A8 0 0
A2 A4 − λ A6 A9 A11 0
0 A5 A7 − λ 0 A12 1
0 0 0 A10 − λ 0 0
0 0 0 0 A13 − λ 0
0 0 0 0 0 A14 − λ
∣∣∣∣∣∣∣∣∣∣∣∣
= 0,
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where
A1 = r2(1− 2b2N∗)− c1T ∗ − α′A∗, A2 = −c′1T ∗ + αA∗ (10)
A3 = −c1N∗, A4 = r1(1− 2b1T ∗)− c′1N∗ − βT ∗
A5 =
α1ρI
∗
(α1 + T ∗)2
− β′I∗, A6 = −βT ∗
A7 =
ρT ∗
α1 + T ∗
− d1 − β′T ∗ + δD
∗
(α2 +D∗)
, A8 = −α′N∗, A9 = αN∗,
A10 = −dA, A11 = −γT ∗ A12 = δα2I
∗
(α2 +D∗)2
A13 = −dD, A14 = bη
(b+ s∗)2
− µ1.
Thus we obtain the following equation
(A10 − λ)(A13 − λ)(A14 − λ)
(
λ3 +B1λ
2 +B2λ+B3
)
= 0, (11)
where B1 = −(A1+A4+A7), B2 = A1A4+A1A7+A4A7−A2A3 and B3 = A5A6+A2A3A7−
A1A4A7. Clearly the characteristic equation (11) has three roots given by λ = A10 = −dA <
0, λ = A13 = −dD < 0 λ = A14 = bη
(b+ s∗)2
− µ1 < 0. We are left with the cubic equation
λ3+B1λ
2+B2λ+B3 = 0. Applying Routh-Hurwitz criterion, the co-existing equilibrium P∗ is
locally asymptotically stable, provided B1 > 0 and B1B2 −B3 > 0. This implies the co-existing
equilibrium P∗ is locally asymptotically stable if A1+A4+A7 < 0 and (A1+A4)(A1A4+A1A7+
A4A7 +A
2
7 −A2A3) +A5A6 < 0.
7 Global Stability of Tumor-free Equilibrium point
Irrespective of the fact that tumor-free equilibrium point is stable or unstable, efforts of doctors
have been always oriented to reach to this point. As tumor cells can be completely destroyed
at this point, thus resulting in complete therapy of the disease. Moreover, in the mean time, it
becomes necessary to find a therapeutic protocol to be able to incline the solution of equations
towards this stable point, irrespective of the initial conditions. For this, we need stimulation
of immune cells and drug administration, which could guarantee the global stability of this
equilibrium point.
In this section, we employ Lyapunov’s direct method [17] to design the desirable disease
eradication protocol. This technique requires selecting a suitable Lyapunov function candidate
and then finding a control law to make this candidate a real Lyapunov function.
Theorem 7.1. The tumor-free steady state, P0 = (
0.4α′ − dAr2
0.4α′b2
, 0,
s∗(dDα2 + 0.4)
d1(dDα2 + 0.4) − 0.4δ ,
0.4
dA
,
0.4
dD
, s∗)
= (N∗, 0, I∗, A∗,D∗, s∗) is globally asymptotically stable if:
(i) b <
µ1
η
,
(ii) g = max
{
2b2N
∗,
β′I2 − β′II∗ − α1ρI2
αAN∗ − αA∗N∗
}
(iii) δα2 >
S − S∗
D∗I +DI∗ −D∗I∗
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Proof. We define the following Lyapunov function,
V (t) =
a
2
(s− s∗)2 + h
2
(A−A∗)2 + c
2
(D −D∗)2 + g
2
(N −N∗)2 + f
2
(I − I∗)2 + m
2
T 2,
where a, h, c, g, f,m are all positive constants. Computing time derivative of V along with (1),
we obtain
dV
dt
= a(s − s∗)(s0 + η
b+ s
s− µ1s) + h(A−A∗)(0.4 − dAA) + c(D −D∗)(0.4 − dDD)
+ g(N −N∗)(r2N (1− b2N)− c1TN − α′AN)
+ f(I − I∗)(s(t) + ρIT
α1 + T
− dII − βIT + δID
α2 +D
)
+mT (r1T (1− b1T )− c′1TN + αAN − βIT − γDT )
≤ −b
dA
(A−A∗)2 − −c
dD
(D −D∗)2 − aµ1(s− s∗)2 + aηb(s− s
∗)2
(b+ s)(b+ s∗)
+ (s − s∗)(I − I∗)
− s
∗
I∗
(I − I∗)2 + α1ρIT (I − I
∗)
α1(α1 + T )
− β′IT (I − I∗) + δα2I(I − I
∗)(D −D∗)
(α2 +D)(α2 +D∗)
+ gr2(N −N∗)2
− gr2b2(N −N∗)3 + αgr2b2N∗2(N −N∗)− c1gNT (N −N∗)− c1gT ∗(N −N∗)2
− gα′N(A−A∗)(N −N∗)− gα′A∗(N −N∗)2 − 2gr2b2NN∗(N −N∗) + gr1T 2 − gr1bT 3
− gc′1T 2(N −N∗)− gc′1N∗T 2 + gαAT (N −N∗) + gαTN∗(A−A∗)− gβIT 2 − gγT 2(D −D∗)
− gγD∗T 2.
Then using (i), (ii) and (iii), we can obtain
dV
dt
< 0. Thus one can guarantee that solution of
equations goes to tumor free equilibrium point, if the parameters of model system (1) satisfy
(i)-(iii).
Corollary 7.2. The co-existing steady state, P∗ = (N
∗, T ∗, I∗, A∗,D∗, s∗) is globally asymptot-
ically stable, provided the following conditions hold:
(i) b <
µ1
η
,
(ii) g = max
{
2b2N
∗, 2b1T
∗,
1
βT ∗2
(s∗ − s+ β′I∗T ∗ − β′IT ∗ − α1ρI∗T ∗ + α1ρIT ∗2 − δα2DI
− δα2ID∗ + δα2DI∗ − δα2D∗I∗), β
′I2 − β′II∗ − α1ρI2 + α1ρIT ∗
αAN∗ − αA∗N∗ − βIT ∗ + βI∗T ∗ ,
−s∗I∗ − sI∗
αN∗A∗T ∗ − αN∗AT ∗ − βI∗T ∗2
}
for some positive constant g.
8 Delayed Model
In comparison to non-delayed models, delay differential equation (DDEs) systems can exhibit
much richer dynamics since a time delay could cause the loss of stability of equilibrium and give
rise to periodic solutions through the Hopf bifurcation. The instabilities and oscillatory behavior
caused by delays are very common, however the delays may also have the opposite effect, namely
that they can suppress oscillations and stabilize equilibria which would be unstable in the absence
of delays.
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Due to chemical transportation of signals and the time needed for differentiation/division
of cells, the production of tumor cells may not be instantaneous but, instead, it exhibits some
time lag. Moreover, due to the immunity, there may be time delay in competition of normal
cells and tumor cells as well. To capture such phenomenon, we introduce two delays into the
non-delayed model (1). Thus we obtain the following system of DDEs corresponding to system
(1) described by the following equations;
dN
dt
= r2N (1− b2N)− c1TN − α′A(t− τ2)N(t− τ2)
dT
dt
= r1T (1− b1T )− c′1TN − βIT − γDT + αA(t− τ1)N(t− τ1)
dI
dt
= s(t) +
ρIT
α1 + T
− dII − βIT + δID
α2 +D
(12)
dA
dt
= 0.4− dAA
dD
dt
= 0.4− dDD
ds
dt
= s0 +
η
b+ s
s− µ1s.
We denote by C the Banach space of continuous functions φ : [−τ, 0] → R6 equipped with
suitable norm, where τ = max{τ1, τ2}. Further let C+ = {φ = (φ1, φ2, φ3, φ4, φ5, φ6) ∈ C :
φi(θ) ≥ 0 ∀ θ ∈ [−τ, 0], i = 1, 2, · · · , 6. The initial conditions corresponding to delayed system
(12) are
N(θ) = φ1(θ), T (θ) = φ2(θ), I(θ) = φ3(θ), A(θ) = φ4(θ), D(θ) = φ5(θ), s(θ) = φ6(θ), (13)
where φ = (φ1, φ2, φ3, φ4, φ5, φ6) ∈ C+.
Qualitative Analysis: Preliminaries
In this subsection, we establish the non-negativity of the solutions of system (12) with initial
conditions (13).
Proposition 8.1. The solutions (N(t), T (t), I(t), A(t),D(t), s(t)) with initial conditions (13) of
the system (12) are non-negative.
Proof. We can rewrite the system (12) in vector form by setting Z = (N,T, I,A,D, s)T ∈ R6
and
F (Z) =


F1(Z)
F2(Z)
F3(Z)
F4(Z)
F5(Z)
F6(Z)


=


r2N (1− b2N)− c1TN − α′A(t− τ2)N(t− τ2)
r1T (1− b1T )− c′1TN − βIT − γDT + αA(t− τ1)N(t− τ1)
s(t) + ρIT
α1+T
− dII − βIT + δIDα2+D
0.4 − dAA
0.4− dDD
s0 +
η
b+ss− µ1s.


(14)
where F : C+ → R6 and F ∈ C∞(R6). Then delayed model (12) becomes
Z˙(t) = F (Zt), (15)
where ≡˙ d
dt
, Zt(θ) = Z(t+ θ), θ ∈ [−τ, 0]. It can be observed from (15) that whenever we choose
Z(θ) ∈ C+ such that Zi = 0, we obtain Fi(z)|Zi(t)=0, Z+ ∈ C+ ≥ 0, i = 1, 2, · · · , 6. Then from
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[18], any solution (15) with Zt(θ) ∈ C+ say Z(t) = Z(t, Z(0)) is such that Z(t) ∈ R60+ ∀ t > 0.
Further we define
P (t) = N(t) + T (t) + I(t) +A(t) +D(t) + s(t).
Then using the similar analysis as done in Theorem 3.1, we have P (t) is bounded and hence are
N(t), T (t), I(t), A(t),D(t), s(t). This completes the proof.
Stability and Bifurcation Analysis
To investigate the local stability of equilibria of system (12), we linearize the system and evaluate
the characteristic equation first at equilibrium P∗. The characteristic equation is∣∣∣∣∣∣∣∣∣∣∣∣
A1 − λ A3 0 A8 0 0
A2 A4 − λ A6 A9 A11 0
0 A5 A7 − λ 0 A12 1
0 0 0 A10 − λ 0 0
0 0 0 0 A13 − λ 0
0 0 0 0 0 A14 − λ
∣∣∣∣∣∣∣∣∣∣∣∣
= 0,
where
A1 = r2(1− 2b2N∗)− c1T ∗ − α′Ae−λτ2 = P − α′Ae−λτ2 ,
A2 = −c′1T ∗ + αAe−λτ1 = Q+ αAe−λτ1 (16)
A3 = −c1N∗, A4 = r1(1− 2b1T ∗)− c′1N∗ − βT ∗
A5 =
α1ρI
∗
(α1 + T ∗)2
− β′I∗, A6 = −βT ∗
A7 =
ρT ∗
α1 + T ∗
− d1 − β′T ∗ + δD
∗
(α2 +D∗)
,
A8 = −α′Ne−λτ2 , A9 = αNe−λτ1 ,
A10 = −dA, A11 = −γT ∗ A12 = δα2I
∗
(α2 +D∗)2
A13 = −dD, A14 = bη
(b+ s∗)2
− µ1. (17)
The characteristic equation is
P0(λ) + P1(λ)e
−λτ1 + P2(λ)e
−λτ2 = 0, (18)
where λ is an eigenvalue and
P0(λ) = λ
3 + λ2(−P −A4 −A7) + λ(A4P +A7P +A4A7 −QA3) + (A5A6 +QA3A7 − PA4A7)
= λ3 +H0λ
2 +H1λ+H2
P1(λ) = −αAA3λ+ αA3A7 = H3λ+H4
P2(λ) = α
′Aλ2 + α′AA4A7 = H5λ
2 +H6.
Case 1: τ1 = τ2 = 0
This case is equivalent to (11) of non-delayed model. Thus P∗ is locally asymptotically stable
provided (9) holds. Similarly, TFE is locally asymptotically stable provided (4) holds and Type
1 dead equilibrium is locally asymptotically stable, if (7) holds.
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Case 2: τ1 > 0, τ2 = 0
In this case, the characteristic equation becomes P0(λ) + P1(λ)e
−λτ1 = 0. We can rewrite this
equation as (
λ3 +H0λ
2 +H1λ+H2
)
+ (H3λ+H4) e
−λτ1 = 0. (19)
If the time delay τ1 is able to destablize P∗ and produces oscillations, this can occur only when
characteristic roots cross the imaginary axis to the right. Let ω > 0 and let λ = iω is a purely
imaginary root of (19). Separating real and imaginary parts, we have
H4 cosωτ1 +H3ω sinωτ1 = H0ω
2 −H2 (20)
H3ω cosωτ1 −H4 sinωτ1 = ω3 −H1ω. (21)
Eliminating τ1 in (20) and (21), we obtain the following sixth-degree polynomial equation
F (ω) = ω6 + h2ω
4 + h1ω
2 + h0 = 0, (22)
where h2 = H
2
0 − 2H1, h1 = H21 − 2H0H2 −H23 and h0 = H22 −H24 . Letting v = ω2 gives the
following simplified system
G(v) = v3 + h2v
2 + h1v + h0 = 0. (23)
Define ∆ = h22−3h1. Next we follow the method described in [19] to investigate for the existence
of positive roots of equation (22). From (23), we have
dG(v)
dv
= 3v2 + 2h2v + h1 (24)
If h0 < 0, since limv→∞G(v) =∞, then we obtain that (22) has atleast one positive root.
When ∆ ≤ 0, dG(v)
dv
≥ 0, that is G(v) is monotonically increasing. Thus, if h0 ≥ 0 and
∆ ≤ 0, then (22) has no positive root.
When ∆ > 0, then graph of G(v) has two critical points v∗1 =
−h2 +
√
∆
3
, v∗2 =
−h2 −
√
∆
3
.
Therefore, if h0 ≥ 0, then from Lemma 2.2 of [19], we can say that (24) has positive roots if and
only if ∆ > 0, v∗1 > 0 and G(v
∗
1) ≤ 0. Assume that equation (24) has three positive roots, given
by v1, v2, v3 respectively. Then (24) has three positive roots ωk =
√
vk, k = 1, 2, 3. Solving (20)
and (21) for τ1, we obtain
τ
(n)
1,k =
1
ωk
arccos
H4(H0ω
2)−H2) +H3ω2(ω2 −H1)
2(H24 + ω
2H23 )
+
2npi
ωk
, k = 1, 2, 3, · · · , n = 0, 1, 2, · · ·
(25)
and ±iωk is pair of purely imaginary roots of (22) with τ (n)1,k .
We further define
τ∗1 = τ
(0)
1,k0
= min
k={1,2,3}
{
τ
(0)
1,k
}
, ω∗ = ωk0 . (26)
We now obtain the transversality condition for Hopf Bifurcation at τ1 = τ
∗
1 . Differentiating (19)
with respect to τ1 and substituting expression for e
−λτ1 from (19), we obtain
dλ
dτ
[
3λ2 + 2λH0 +H1 − (H3 −H3λτ1 −H4τ1)(λ
3 +H0λ
2 +H1λ+H2)
H3λ+H4
]
= −λ(λ3 +H0λ2 +H1λ+H0)
Thus we have (
dλ
dτ
)−1
=
H3
λ(H3λ+H4)
− 3λ
2 + 2λH0 +H1
λ(λ3 +H0λ2 +H1λ+H2)
− τ1
λ
.
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Evaluating
(
dλ
dτ
)−1
at τ1 = τ
∗
1 (i.e.λ = iω
∗) and taking real part, we obtain
Re
[(
dλ
dτ
)−1 ∣∣∣
τ1=τ∗1
]
=
3ω4 + 2ω2(H20 − 2H1) + (H21 − 2H0H2 −H23 )
H23ω
2 +H24
=
G′(ω∗2)
H23ω
∗2 +H24
We have G(v) is non-increasing and positive. Thus
sign
{(
dRe(λ)
dτ
) ∣∣∣
τ1=τ∗1
}
= sign
{(
dλ
dτ
)−1 ∣∣∣
τ1=τ∗1
}
= sign{G′(ω∗2)}.
Hence if G′(ω∗2) 6= 0, then transversality condition holds. Summarizing the above, we have the
following theorem
Theorem 8.2. For τ1 > 0, τ2 = 0, assume that condition (9) holds. If either h0 < 0 or h0 ≥ 0,
∆ > 0, v∗1 > 0 and G(v
∗
1) < 0, then the Endemic equilibrium P∗ is locally asymptotically stable
for 0 < τ1 < τ
∗
1 , where
τ∗1 =
1
ω∗
arccos
H4(H0ω
2)−H2) +H3ω2(ω2 −H1)
2(H24 + ω
2H23 )
+
2npi
ω∗
. (27)
Furthermore, if G′(ω∗2) 6= 0, then system (12) undergoes Hopf bifurcation to periodic solutions
at P∗ at τ1 = τ
∗
1 .
Remark 8.3. If h0 ≥ 0 and ∆ ≤ 0, then equation (24) has no positive real root, thus the
equilibrium P∗ is locally asymptotically stable for all τ1 > 0.
Case 3: τ2 > 0, τ1 = 0
In this case, the characteristic equation becomes P0(λ) + P1(λ)e
−λτ2 = 0. We can rewrite this
equation as (
λ3 +H0λ
2 +H1λ+H2
)
+
(
H5λ
2 +H6
)
e−λτ2 = 0. (28)
Using the similar analysis as done in case 2, we have the following theorem.
Theorem 8.4. For τ2 > 0, τ1 = 0, assume that condition (9) holds. If either h0 < 0 or h0 ≥ 0,
∆ > 0, v∗1 > 0 and G(v
∗
1) < 0, then the Endemic equilibrium P∗ is locally asymptotically stable
for 0 < τ2 < τ
∗
2 , where
τ∗2 =
1
ω∗
arccos
(H0ω
2 −H2)
2(H6 − ω2H5) +
2npi
ω∗
(29)
Furthermore, if G′(ω∗2) 6= 0, then system (12) undergoes Hopf bifurcation to periodic solutions
at P∗ at τ2 = τ
∗
2 .
Case 4: τ2 > 0, τ1 ∈ (0, τ∗1 )
In this case, we consider τ2 as a parameter and fix τ1 at a point in its stable interval. At P∗, the
characteristic equation takes the following form;
P (λ, τ1, τ2) =
(
λ3 +H0λ
2 +H1λ+H2
)
+ (H3λ+H4) e
−λτ1 +
(
H5λ
2 +H6
)
e−λτ2 = 0. (30)
Assume that (30) has purely imaginary root given by λ = iω. Substituting in (30) and separating
real and imaginary parts, we obtain
H0ω
2 −H2 −H4 cosωτ1 −H3ω sinωτ1 = (H6 −H5ω2) cos ωτ2 (31)
−ω3 +H1ω +H3ω cosωτ1 −H4 sinωτ1 = (H6 −H5ω2) sinωτ2. (32)
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Eliminating τ2 in (31) and (32), we obtain the following polynomial equation;
ω6 + ω4(H20 − 2H1 −H25 ) + ω3(2H4 sinωτ1 − 2H0H3 sinωτ1)
+ ω2(H23 − 2H0H2 +H21 + 2H5H6 − 2H1H3 cosωτ1) = 0, (33)
which is a sixth-degree polynomial in ω. If (C1) holds, then let we denote the six positive roots
of (33) as ωk, k = 1, 2, · · · , 6. Solving (31)-(32) for τ2, we obtain
τn2,k =
1
ωk
arccos
H0ω
2 −H2 −H4 cosωτ1 −H3ω sinωτ1
H6 −H5ω2 +
2npi
ωk
, k = 1, 2, · · · , 6 n = 0, 1, 2 · · ·
(34)
and ±ωk is pair of purely imaginary root of (33) with τn2,k. For simplicity we define
τ∗20 = τ
0
2,k = min
k=1,2,··· ,6
{
τ02,k
}
, ω∗ = ωk0 . (35)
Now, differentiating (30) with respect to τ2 and further simplifying for transversality condition,
we obtain
Re
[(
dλ
dτ
)−1 ∣∣∣
τ1=τ∗1
]
=
2ωH0 cosωτ2 + (H1 − 3ω2) sinωτ2
ω(H6 −H5ω2) +
H3 sinω(τ2 − τ1)
ω(H6 −H5ω2) +
2H5
(H6 −H5ω2)
∣∣∣
τ∗
20
.
Since (C2) holds, the transversality condition holds. Thus we have the following result.
Theorem 8.5. Assume condition (C1)-(C2) hold and τ1 ∈ (0, τ∗1 ), then P∗ is locally asymptot-
ically stable for τ2 ∈ (0, τ∗20) and system (12) undergoes Hopf bifurcation to periodic solutions at
P∗ for τ2 = τ
∗
20, where
(C1): Equation (33) has six positive roots,
(C2): H6 > H5ω
2
∣∣∣
τ∗
20
, H1 > 3ω
2
∣∣∣
τ∗
20
.
Case 5: τ1 > 0, τ2 ∈ (0, τ∗2 )
In this case, τ2 is fixed at a point in its stable interval and τ1 is considered as a parameter. At
P∗ we have the same characteristic equation as (30). Following the similar procedure as in case
4, we substitute λ = iω and separate the real and imaginary parts. Thus we obtain
H4 cosωτ1 +H3ω sinωτ1 = H0ω
2 −H2 − (H6 −H5ω2) cosωτ2 (36)
H3ω cosωτ1 −H4 sinωτ1 = ω3 −H1ω + (H6 −H5ω2) sinωτ2.
Thus we obtain
ω6 − (2H5 sinωτ2)ω5 + (H20 +H25 + 2H0H5 cosωτ2)ω4 + (2H1H5 sinωτ2 + 2H6 sinωτ2)ω3 (37)
+ (−2H5H6 − 2H0H2 − 2H2H5 cosωτ2 − 2H0H6 cosωτ2 +H21 −H23 )ω2 − (2H1H6 sinωτ2)ω
+ (H22 +H
2
6 − 2H2H6 cosωτ2 −H24 ) = 0 (38)
and
τn1,k =
1
ωk
arccos
H4(H0ω
2 −H2 − (H6 −H5ω2) cosωτ2) +H3ω(ω3 −H1ω + (H6 −H5ω2) sinωτ2)
2(H24 +H
2
3ω
2)
+
2npi
ωk
,
(39)
k = 1, 2, · · · , 6 n = 0, 1, 2 · · · .
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Furthermore, we have
sign
[
Re
[(
dλ
dτ
)−1 ∣∣∣
τ1=τ
∗
1
] ]
= sign
[cosωτ1(3H3ω3 −H1H3ω + 2H0H4ω)− sinωτ1(3ω3H4 −H1H4 − 2H0H3ω2) +H3 − 2H5ω sinω(τ1 − τ2)
ω(H24 +H
2
3ω
2)
]
.
Theorem 8.6. Assume conditions (C1’)-(C2’) hold and τ2 ∈ (0, τ∗2 ), then P∗ is locally asymptotically
stable for τ1 ∈ (0, τ∗10) and system (12) undergoes Hopf bifurcation to periodic solutions at P∗ for τ1 = τ∗10,
where
(C1’): Equation (37) has six positive roots,
(C2’): 3H3ω
3 + 2ωH0H4 > H1H3ω, 3ω
2H4 < H1H4 + 2H0H3ω
2 and 2H5ω sinω(τ1 − τ2) < 0.
Case 6: τ1 = τ2 = τ
In this case, characteristic equation is
P (λ, τ) =
(
λ3 +H0λ
2 +H1λ+H2
)
+
(
H5λ
2 +H3λ+H7
)
e−λτ = 0, (40)
where H7 = H4 +H6. Then substituting λ = ıω in (40) and following the similar procedure, we obtain
τ ik =
1
ωk
arccos
H3(H0ω
2 −H2) + (H7 −H5ω2)(ω2 −H1)
2H3(H7 −H5ω2) +
2npi
ωk
, k = 1, 2, · · · , 6 n = 0, 1, 2 · · · . (41)
and
ω6 + (H20 −H25 − 2H1)ω4 + (H21 − 2H0H2 + 2H5H7) + (H22 −H27 ) = 0. (42)
Furthermore, we have
sign
[
Re
[(
dλ
dτ
)−1 ∣∣∣
τ=τ∗
]]
= sign
[
(H7 −H5ω2)
(
2H0ω cosωτ + (H1 − 3ω2) sinωτ
)
−H3ω
(
(H1 − 3ω2) cos ωτ − 2H0ω sinωτ
)
+ 2ωH5(H7 −H5ω2)−H23ω
ω
(
(H5ω2 −H7)2 +H23ω
2
)
]
.
Theorem 8.7. Assume conditions (C1”)-(C2”) hold and τ ∈ (0, τ∗), then P∗ is locally asymptotically
stable for τ ∈ (0, τ∗) and system (12) undergoes Hopf bifurcation to periodic solutions at P∗ for τ = τ∗,
where
(C1”): Equation (40) has six positive roots,
(C2”): (H7−H5ω2)
(
2H0ω cosωτ + (H1 − 3ω
2) sinωτ
)
+2ωH5(H7−H5ω
2) > H3ω
(
(H1 − 3ω
2) cosωτ − 2H0ω sinωτ
)
+
H23ω.
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9 Numerical Simulations
9.1 Original Model
We begin by studying the original model (1) without the delay.
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(a) Cell Evolution with time
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Figure 1: Evolution of cells for (a) parameters given in (43) and (b) for various β
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Figure 2: Evolution of cells for (a) various α2 and (b) R0 for various α2 and δ
For the numerical simulation of our model (1), we consider the parameter values as,
r1 = 1, r2 = 0.5, s0 = 0.33, b1 = 1, b2 = 1, c1 = 0.5, c1
′ = 0.5, α = 0.003, α′ = 0.003, β = 0.02, (43)
β′ = 0.02, γ = 0.2, d1 = 0.2, dD = 1, dA = 0.04, η = 0.5, µ1 = 0.3, b = 0.5, ρ = 0.01, α1 = 0.3, (44)
δ = 0.08, α2 = 0.1. (45)
Corresponding to these parameter values, the equilibrium points are P1 = (0, 0, 18.2923, 10, 0.4, 2.4877),
P2 = (0, 0.7403, 8.9826, 10, 0.4, 2.4878) and P3 = (0.4170, 0.5230, 10.6200, 10, 0.4, 2.4877). For this set of
parameters, the reproduction number is R0 = 0.3526. Here the four equilibrium points exist and tumor-
free equilibrium does not exists. The simulation results for the model system (1) corresponding to these
parameter values and initial population (30000, 10000, 10000, 50000, 20000, 20000) are shown in Figure
1(a).
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It can be observed from the time portrait that the system is asymptotically stable, with the solutions
converging to the equilibrium point P3. Furthermore, we observe the evolution of Tumor cells with
variations in parameters β and BT-immune threshold rate α2. We can observe from Figure 1(b) that
as the competition term β increases, population of Tumor cells decreases. This is due to competition
between the Tumor cells and immune cells.
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(a) Evolution of tumor cells with various interaction
terms.
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Figure 3: Solution for variable-inlfux with BT-immune term converges to equilibrium state T*=
0.3005 for tumors and N*= 0.6399 for normal cells
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(a) Evolution of immune cells with various interaction
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(b) Evolution of cells under steady and variable influx.
Figure 4: Solution for steady immune converges to (N*, T*)= (0.0976,0.8431) and for variable
influx it converges to (N*, T*)= (0.6390, 0.3010)
The behaviours of tumor, normal and immune cells are studied using similar parameter set as before.
In figure 3(a) and 3(b), the behaviours of the tumor and normal cells are illustrated in the presence of
various interaction components.
As the system of tumor cells interacts with immune cells in steady influx model (black circles in fig.3(a)
), the saturation value is high enough to consider the system dead. The population is simulataneously low
for the normal cells as shown in fig. 3(b). This gives us the idea to supplement the immune cell growth to
counteract the rise of tumor cells. A variable influx is then assumed in system with immunity alone, and
the pronounced effect of variable influx is immediately observed as the tumor population comes down,
while increasing the normal cells population (red dashed line in fig. 3(a) and 3(b)). Cancer inducing
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(a) Evolution of tumor cells with variation in µ1
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Figure 5: Evolution of tumor and normal cells for various µ1 and η
(a)
Figure 6: phase portrait for model 1. Solution trajectories converge to its equilibrium state (N*,
T*, A*)= (0.6399, 0.3005, 9.961) starting from different initial conditions.
arsenic is then introduced in the system with the variable influx model and the tumor population is
raised, and decreasing the normal population. The is due to the fact that arsenic converts a fraction of
normal cells into tumorous. Black tea is introduced in the system in form drug and while this does affect
the population of tumor and normal cells (green dash-dot in the figure), the introduction of BT-immune
interaction has great impact in the system as shown in fig.3(a)(magenta dots).
For variable influx model we observe that immune cells saturate at a higher value than for the steady
influx and the effect is even pronounced if BT-immune term is incorporated. This indicates that it may be
possible to reach a healthy outcome with an immunomodulator and variable immune response, working
in tandem, without the intervention of chemotherapeutic drugs. Indeed, it depends on the values of the
parameters and the severity of the disease, but what we are able to show here is that it may be possible
to dispense with chemotherapy or at least reduce its application to a large degree if suitable protocols
with BT and immune response could be achieved.
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While the perfect cure for cancer is still not possible, we can aim to provide a good and prolonged life.
One way to acheive that is by keeping the tumor cells always under control and lower than normal cell
population. This can be achieved by extensive chemotherapy but the price is paid in form of painful side-
effects. Starting with a small tumor population, and supplementing the system with immunomodulatory
effects of BT, we observe as shown in fig.4(b), that tumor population can be kept below a certain threshold
for a longer amount of time.
The variation in the immune cells in system(1)is brought about by s(t). These stimulated immune
cells are assumed to have production rate of η and death rate of µ1. Higher rate of production of immune
cells has larger effect on tumor population as shown in fig.5(a). One has to be careful here as large
production rate can lead to immune cell proliferation and immune upon immune crowding. A similar
scenerio is for death of stimulated immune cells (see fig.5(b)) and a smaller death rate can lead to similar
problems as that of larger production rate.
Considering the parameteric values in sec. 9.1, the model system(1) has the equilibrium state solution
(N*,T*,A*)= (0.6399, 0.3005, 9.961), and the solution curves stabilize to its equilibrium state(shown in
phase portrait 6(a) )
9.2 Delayed Model
In this section we present the results obtained for a delayed system (12). As discussed in Section 8, time
delay of τ1 and τ2 is incorporated in the normal and tumor cells respectively. This delay could be due
immunity in the system .
A delay τ1 = τ2 = τ has been added in Arsenic-Normal cell interaction. This kind of delay in the
system can be analysed analytically as done in Section 8. Physically this delay implies that the arsenic
in the system converts the normal cell into tumorous at a later time. The effect of the delay doesn’t have
a large impact over the fraction of cells as shown in fig 7(a). For a delay of τ = 5 the normal cells fare
better very slightly before converging to its stable equilibrium point (see fig 7(b))
A more physical delay in the form of delay in immune response is also studied. While the system
is complex, the analytic research about the characteristic equation can be carried out similarly, and we
present the numerical analysis in this section to show the dynamical behaviour of the system with delayed
immune response.
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Figure 7: Solution converges to its equilibrium state (N*, T*)= (0.6439, 0.3005)
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Figure 8: Solution converges to its equilibrium state (N*, T*)= (0.6439, 0.3005)
dN
dt
= r2N (1− b2N)− c1TN − α′AN
dT
dt
= r1T (1− b1T )− c′1TN − βI(t− τ)T − γDT + αAN
dI
dt
= s(t) +
ρI(t− τ)T
α1 + T
− dII − βI(t− τ)T + δI(t− τ)D
α2 +D
(46)
dA
dt
= a0 − dAA
dD
dt
= b0 − dDD
ds
dt
= s0 +
η
b+ s
s− µ1s.
A delay in tumor-immune and BT-immune response is studied in eqn.46. A delay of τ = 5 has
considerable effect on fraction of cells as shown in fig 8(a). The fraction of tumor cells rises above the
normal cells before converging towards equilibrium point (N*, T*)= (0.6439, 0.3005), as observed in Fig.
8(b).
10 Conclusion
We have written down a model for the growth of cancer cells under the exposure of an environmental
carcinogen and a mitigating agent. We deliberately exclude any chemotherapeutic treatment in the model
in order to test and establish a possible protocol without its use. The treatment of the model follows
two routes, one analytical looking for the local stability of tumor-free equilibrium, dead equilibrium and
local and global stabilities of endemic equilibrium from the model.The Reproduction Number, which is
an indicator of rate of spread has been computed by using next generation matrix method. The local
stability of tumor-free equilibrium, dead equilibrium, endemic equilibrium and global stability of endemic
equilibrium have been analyzed. Furthermore, stability and bifurcation analysis of delayed model have
been discussed.
A model system with compromised immune system has been studied with prime focus on using
immunotherapy to obtain best results within certain general parameters. A comparison has been made
between a constant influx model of immune cells studied earlier and the variable influx model of immune
cells under consideration. Black tea, which has been studied extensively in literature is used as an
immunomodulator to curb the side- effects of traditional chemotherapeutic treatments. Along with
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variable influx model an important BT-immune interaction has been incorporated in the system. Constant
influx of immune cells saturates the tumor cells at unhealthy levels even under BT-immune interaction.
The maximum effect on tumor cells comes from combining the two predominant factors, namely, variable
influx and BT-immune interaction. Starting from as high as 10 percent tumor cell count to begin with,
the tumor cell population never exceeds the normal cells at any time during the evolution. The effect of
rate of production of immune cells and their death have been investigatyed and a higher production rate,
and slower death rate of immune cells have greater effect on tumor cells; however this has to be exercised
with caution as this may lead to immune proliferation and immune upon immune crowding.
Finally, a physically relevant scenario with delay has been introduced. A delay in arsenic-normal
cell interaction some impact on the general result, albeit small quantitative shifts in counts. On the
other hand, a delay in immune cell response has considerable effect on the fractional count of cells. A
delay of τ = 5 results in higher peak value of tumor cells and even surpasses the fraction of normal
cells highlighting the importance of rapid immune response in addition to the variable immune influx in
fighting cancer.
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